No Data
No Data
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025
Cocrystal Pharma Analyst Ratings
H.C. Wainwright Maintains Cocrystal Pharma(COCP.US) With Buy Rating, Maintains Target Price $7
Cocrystal Pharma Reports Positive Phase 1 Study Results
Cocrystal Pharma Reports Phase 1 Results With Oral, Broad-Acting Antiviral Drug CDI-988 For Prophylaxis And Treatment Of Norovirus, Coronaviruses And Other Viral Infections; Data Show Favorable Safety And Tolerability With Dosing Up To 800 Mg For 10...
Express News | Cocrystal Pharma Inc - Plans Human Challenge Study in 2025 for Norovirus
Unlock the Full List